The Somascan® assay: biomarker discovery to delivery

Watch the webinar now

ABSTRACT

The SomaScan® assay is a proteomic platform that uses single-stranded DNA engineered with aromatic hydrocarbon side chains for binding to protein targets. The SomaScan® assay has been used to identify signals as surrogates for clinical outcomes, discover proteins associated with disease states, and correlate protein measurements with genetic variants.

SomaLogic-design-ideas-23

Sheri K. Wilcox, Ph.D

Scientific Liaison and Technical Services, SomaLogic Inc

Sheri K. Wilcox is Senior Director, Scientific Liaison and Technical Services, at SomaLogic, Inc. in Boulder, Colorado. She received her B.S. in Chemistry from Vanderbilt University in Nashville, Tennessee, in 1993 and her Ph.D. in Macromolecular and Cellular Structure and Chemistry from The Scripps Research Institute in La Jolla, California, in 1999. She completed two years of post-doctoral studies at Pharmacia and Upjohn in Kalamazoo, Michigan, and then joined SomaLogic, Inc. in 2001, where she has been contributing to the generation and utility of novel protein affinity reagents based on Slow-Off rate Modified Aptamers (SOMAmer® reagents) for over 19 years.

Share with colleagues

More webinars

WebinarUsing plasma proteomics to understand diseases of the brain: alzheimer’s & cerebral small vessel disease

This presentation will demonstrate how proteins measured in blood decades before dementia onset can be combined with genetic data to (1) identify novel early biomarkers for Dementia, Alzheimer’s disease, and brain MRI characteristics indicative of Cerebral Small Vessel disease, and (2) better understand the molecular pathways altered in the preclinical and prodromal phase of neurodegenerative disease.

Learn more

WebinarDeveloping microbiome-directed therapeutics for treating childhood undernutrition

This 1-hour talk covers how researchers are testing the hypothesis that perturbations in the normal development of the gut microbiome are causally related to childhood undernutrition, a devastating global health problem whose long-term sequelae include metabolic and immune dysfunction, stunting, and neurodevelopmental abnormalities, which remains largely refractory to current therapeutic interventions.

Learn more

WebinarProteomic risk scores can help identify high-risk patients and monitor short- and long-term effects of treatment

In this 1-hour discussion, you will learn how large-scale proteomics can be leveraged for multiple applications in the field of oncology. The focus will be on 2 new avenues of oncology research. The first is using proteomic risk scores to monitor the cardiotoxic effects of anthracycline treatment and identify patients who may benefit from cardioprotective therapy. The other is developing blood-based protein tests for stratifying lung cancer susceptibility. From biomarker discovery to medicine application and the potential to inform and impact patients’ standard of care—there is a lot to learn and look forward to in oncology research using proteomics.

Learn more

Explore webinars in our interactive viewer